Failure of intravenous and intrathecal cytarabine to modify central nervous system IgG synthesis in multiple sclerosis.
To study the nature of the multiple sclerosis (MS) central nervous system (CNS) immune reaction, cytarabine (ara-C) was administered intravenously to three patients and intrathecally to another seven. Although intravenous administration severely suppressed circulating leukocytes derived fom the bone marrow, there was no change in de novo CNS IgG synthesis (rate or presence of CSF IgG oligoclones). Therefore, the MS CNS immune reaction can persist in the presence of severe granulocytopenia and severe monocytopenia of one to two weeks' duration. In four patients who were given ara-C intrathecally, cytotoxic levels (> 10 micrograms/ml) were present for a least 24 hours. A brief elevation in CSF albumin indicated transient damage to the blood-brain barrier. Leukopenia did not result in the seven patients treated intrathecally, and de novo CNS IgG synthesis did not change or was transiently increased. Assuming that cytotoxic levels in CSF diffused to the CNS sites responsible for synthesizing IgG, results indicate that CNS IgG synthesis does not depend on in situ rapid turnover of immune cells. None of the ten patients demonstrated neurological improvement or persistent adverse effects.
D000328:Adult; D002490:Central Nervous System / Q000378:metabolism*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006423:Hemianopsia / Q000139:chemically induced; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis*; D007275:Injections, Intravenous; D007278:Injections, Spinal; D008297:Male; D008580:Meningism / Q000139:chemically induced; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*
D007074:Immunoglobulin G; D003561:Cytarabine